Home LiteratureArticle Details
PMID: 26250831 Published · ppublish English Journal Article

Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.

Digestive diseases and sciences ·Vol. 60 ·No. 10 ·2015-10-00 ·Pages 3142-8

Perumpail RB, Wong RJ, Ahmed A, Harrison SA

Abstract

Type 2 diabetes mellitus, obesity, and the metabolic syndrome (MS) have been growing in prevalence in the USA and are independent risk factors for the development of hepatocellular carcinoma (HCC). Nonalcoholic fatty liver disease (NAFLD), the hepatic manifestation of the MS, with or without nonalcoholic steatohepatitis (NASH) can predispose to HCC in the absence of cirrhosis or advanced fibrosis. Nevertheless, the US literature investigating non-cirrhotic HCC in the setting of NAFLD/NASH and MS is lacking. To describe a retrospective case series of patients who developed HCC without cirrhosis in the setting of NAFLD/NASH or features of the MS. We identified NAFLD/NASH-associated HCC cases arising in the absence of cirrhosis between January 2010 and September 2012 from a tumor board database at Brooke Army Medical Center (BAMC). Of 44 cases of HCC reviewed, six cases of non-cirrhotic HCC associated with NAFLD/NASH and/or MS were identified. Only one patient underwent partial hepatectomy with curative intent. The other five might have been candidates for potential curative partial hepatectomy or liver transplantation had they been diagnosed earlier. Our case series highlights the development of NAFLD/NASH and MS-associated HCC in the absence of cirrhosis in the US population and raises the important question of HCC screening for this at-risk group.

Keywords
Hepatocellular carcinoma Metabolic syndrome NAFLD NASH Nonalcoholic fatty liver disease Nonalcoholic steatohepatitis
MeSH Terms
Age Distribution Aged Carcinoma, Hepatocellular/diagnosis,epidemiology,therapy Cohort Studies Comorbidity Databases, Factual Female Humans Incidence Liver Neoplasms/diagnosis,epidemiology,therapy Male Metabolic Syndrome/diagnosis,epidemiology,therapy Middle Aged Non-alcoholic Fatty Liver Disease/diagnosis,epidemiology,therapy Prognosis Retrospective Studies Risk Assessment Sex Distribution Survival Rate United States/epidemiology
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Perumpail Ryan B
Division of Gastroenterology and Hepatology, Liver Transplant Program, Stanford University School of Medicine, 750 Welch Road, Suite #210, Stanford, CA, 94304, USA. rperumpail@gmail.com.
Wong Robert J
Division of Gastroenterology and Hepatology, Alameda Health System, Highland Hospital Campus, 1411 East 31st Street, Oakland, CA, 94602, USA. rowong@alamedahealthsystem.org.
Ahmed Aijaz
Division of Gastroenterology and Hepatology, Liver Transplant Program, Stanford University School of Medicine, 750 Welch Road, Suite #210, Stanford, CA, 94304, USA. aijazahmed@stanford.edu.
Harrison Stephen A
Division of Gastroenterology, San Antonio Military Medical Center, 3841 Roger Brooke Drive, Fort Sam Houston, TX, 78234, USA. stephen.a.harrison.mil@mail.mil.
References (42)
42 references, click to expand
  1. Management of hepatocellular carcinoma: an update.
    Hepatology. 2011 Mar;53(3):1020-2 PMID: 21374666
  2. Leptin and liver fibrosis: a matter of fat.
    Gastroenterology. 2002 May;122(5):1529-32 PMID: 11984539
  3. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.
    N Engl J Med. 2003 Apr 24;348(17):1625-38 PMID: 12711737
  4. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1.
    Cancer Res. 2011 Jul 1;71(13):4366-72 PMID: 21540236
  5. Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation.
    Diabet Med. 2006 May;23(5):469-80 PMID: 16681555
  6. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study.
    Am J Gastroenterol. 2012 Jan;107(1):46-52 PMID: 22085817
  7. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review.
    Clin Gastroenterol Hepatol. 2012 Dec;10(12):1342-1359.e2 PMID: 23041539
  8. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database.
    Hepatology. 2011 Aug;54(2):463-71 PMID: 21538440
  9. Increasing prevalence of the metabolic syndrome among u.s. Adults.
    Diabetes Care. 2004 Oct;27(10):2444-9 PMID: 15451914
  10. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace.
    J Hepatol. 2012 Jun;56(6):1384-91 PMID: 22326465
  11. Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link.
    Cancer. 2009 Dec 15;115(24):5651-61 PMID: 19834957
  12. Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3.
    World J Gastroenterol. 2011 Sep 14;17(34):3922-32 PMID: 22025881
  13. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study.
    Gut. 2005 Apr;54(4):533-9 PMID: 15753540
  14. Obesity, inflammation, and insulin resistance.
    Gastroenterology. 2007 May;132(6):2169-80 PMID: 17498510
  15. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial.
    Br J Cancer. 2001 Apr 6;84(7):886-91 PMID: 11286466
  16. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
    N Engl J Med. 2006 Nov 30;355(22):2297-307 PMID: 17135584
  17. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma.
    Cancer. 2010 Apr 15;116(8):1938-46 PMID: 20166205
  18. Nonalcoholic fatty liver disease: a systematic review.
    JAMA. 2015 Jun 9;313(22):2263-73 PMID: 26057287
  19. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection.
    Hepatology. 2010 May;51(5):1820-32 PMID: 20432259
  20. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
    N Engl J Med. 2010 May 6;362(18):1675-85 PMID: 20427778
  21. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma.
    Clin Gastroenterol Hepatol. 2011 May;9(5):428-33; quiz e50 PMID: 21320639
  22. Hepatocellular carcinoma.
    Lancet. 2003 Dec 6;362(9399):1907-17 PMID: 14667750
  23. Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis.
    Cancer Prev Res (Phila). 2012 Apr;5(4):544-52 PMID: 22467080
  24. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.
    Gastroenterology. 2011 Jan;140(1):124-31 PMID: 20858492
  25. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States.
    Hepatology. 2002 Dec;36(6):1349-54 PMID: 12447858
  26. STAT3 activation in monocytes accelerates liver cancer progression.
    BMC Cancer. 2011 Dec 05;11:506 PMID: 22136659
  27. Pathology of fatty liver disease.
    Mod Pathol. 2007 Feb;20 Suppl 1:S40-8 PMID: 17486051
  28. Sustained JNK1 activation is associated with altered histone H3 methylations in human liver cancer.
    J Hepatol. 2009 Feb;50(2):323-33 PMID: 19041150
  29. Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis?
    Arch Pathol Lab Med. 2008 Nov;132(11):1761-6 PMID: 18976012
  30. Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications.
    Gut. 2010 Oct;59(10):1303-7 PMID: 20650925
  31. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis.
    Gastroenterology. 2007 Jun;132(7):2557-76 PMID: 17570226
  32. Pharmacological characterization of a small molecule inhibitor of c-Jun kinase.
    Am J Physiol Endocrinol Metab. 2008 Nov;295(5):E1142-51 PMID: 18728225
  33. Global cancer statistics.
    CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90 PMID: 21296855
  34. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes.
    Gastroenterology. 2009 May;136(5):1601-8 PMID: 19208359
  35. Prevalence and trends in obesity among US adults, 1999-2008.
    JAMA. 2010 Jan 20;303(3):235-41 PMID: 20071471
  36. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression.
    Cell. 2010 Jan 22;140(2):197-208 PMID: 20141834
  37. Features, diagnosis, and treatment of nonalcoholic fatty liver disease.
    Clin Gastroenterol Hepatol. 2012 Aug;10(8):837-58 PMID: 22446927
  38. Management of hepatocellular carcinoma.
    Hepatology. 2005 Nov;42(5):1208-36 PMID: 16250051
  39. Effect of weight loss with or without orlistat treatment on adipocytokines, inflammation, and oxidative markers in obese women.
    Hormones (Athens). 2006 Oct-Dec;5(4):259-69 PMID: 17178701
  40. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies.
    Gut. 2013 Apr;62(4):606-15 PMID: 22773548
  41. Insulin-like growth factor I is a comitogen for hepatocyte growth factor in a rat model of hepatocellular carcinoma.
    Hepatology. 2002 Nov;36(5):1089-97 PMID: 12395318
  42. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology. 2012 Jun;55(6):2005-23 PMID: 22488764
Article Info
Journal
Digestive diseases and sciences
Abbr.
Dig Dis Sci
ISSN
1573-2568
Published
2015-10-00
Epub
2015-00-07
Pages
3142-8
Language
English
Region
United States
NLM ID
7902782
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com